Aquestive Therapeutics Enters New Credit Agreement and Terminates Prior Facility

Aquestive Therapeutics Inc. entered into a new credit agreement, terminated its prior credit agreement, reported first-quarter financial results, created a direct financial obligation under the new facility, and conducted an unregistered sale of equity securities, according to an 8-K filed with the SEC on May 13 2026.

The filing affects Aquestive Therapeutics shareholders, debt holders, and operational counterparties. Item 2.02 discloses results of operations and financial condition for the quarter ended March 31 2026. Item 3.02 covers the unregistered sale of equity securities tied to the new financing arrangement.

The new credit agreement triggers immediate financial obligations whose exact dollar size is detailed in the exhibits filed with the document.

The operational change replaces the terminated credit agreement with a new facility whose terms govern interest, repayment, and covenants going forward. The prior agreement ended on May 13 2026 under Item 1.02. The new agreement took effect the same day under Item 1.01.

Item 2.03 confirms creation of the direct financial obligation on that date. The unregistered equity issuance closed concurrently with the financing.

Downstream effects include updated disclosure obligations that require the company to file the full credit agreement and related exhibits within the standard four-business-day window already satisfied by this 8-K. The new lender gains contractual rights and remedies spelled out in the agreement.

Aquestive must observe any financial covenants and reporting milestones in the new facility, which in turn determine when subsequent 8-K or 10-Q filings will reflect compliance or breaches. The equity issuance alters the company's capitalization and requires updated disclosure in its next Form 10-Q or registration statement if the securities are later registered.

This filing is the latest in Aquestive's sequence of financing disclosures. The company has previously used similar credit facilities and equity sales to fund operations, per its historical SEC filings. The new agreement and equity component follow the pattern of prior capital raises without triggering immediate registration requirements under the Securities Act.